Astria Therapeutics to Present at Upcoming Investment Conferences

Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) has announced presentations at two upcoming investment conferences. CEO Jill C. Milne will give a corporate overview and discuss the lead program STAR-0215, a treatment for hereditary angioedema, at the H.C. Wainwright Global Investment Conference on September 12. She will also participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on September 29. Archived replays of the presentations will be available on the company's website for 30 days following the events.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will be presenting at two upcoming investment conferences:

• H.C. Wainwright 24^th Annual Global Investment Conference: Jill C. Milne, Ph.D., Chief Executive Officer at Astria will present a corporate overview and provide information on lead program STAR-0215. An on-demand webcast of the presentation can be accessed beginning at 7:00am ET on Monday, September 12, at the following link: https://journey.ct.events/view/aef48288-dfa2-462a-b6ec-9b593a73d637.
• Ladenburg Thalmann 2022 Healthcare Conference: On September 29, Dr. Milne will present during a fireside chat at 1:30pm ET. A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/ladenburg8/atxs/2450816.

Archived replays of the presentations will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005087/en/

Astria Contacts:

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

When will Astria Therapeutics present at the H.C. Wainwright Global Investment Conference?

Astria Therapeutics will present at the H.C. Wainwright Global Investment Conference on September 12 at 7:00 am ET.

What is STAR-0215 and its significance for Astria Therapeutics?

STAR-0215 is Astria Therapeutics' lead program, a monoclonal antibody in clinical development for the treatment of hereditary angioedema.

When is the Ladenburg Thalmann 2022 Healthcare Conference?

The Ladenburg Thalmann 2022 Healthcare Conference will take place on September 29 at 1:30 pm ET.

Where can I find replays of the presentations by Astria Therapeutics?

Archived replays of the presentations will be available on Astria Therapeutics' website for 30 days after the events.

Who is presenting for Astria Therapeutics at the investment conferences?

Jill C. Milne, Ph.D., the CEO of Astria Therapeutics, will be presenting at both investment conferences.